Utilization of Measles-Containing Vaccines in Children Aged 12 to 47 Months
Overview
This study analyzed the patterns of measles-containing vaccine (MCV) selection among children aged 12 to 47 months in King County, Washington, from 2015 to 2025. It found that 15% of children received the measles, mumps, rubella, and varicella (MMRV) vaccine as their first dose.
Background
Measles-containing vaccines are critical for preventing measles and its transmission, with the first dose recommended between 12 and 15 months of age. The Advisory Committee on Immunization Practices (ACIP) has made recommendations regarding the use of MMRV and its safety, particularly concerning febrile seizures.
Data Highlights
Vaccine Type
Number of Children
Percentage
MMR + VAR
136,084
64%
MMR Alone
37,938
18%
MMRV
31,430
15%
VAR Alone
7,993
4%
Key Findings
15% of children received MMRV as their first MCV and VCV dose.
Children receiving MMRV were more likely to be from minoritized racial and ethnic groups.
64% of children received coadministered MMR + VAR, while 18% received MMR alone.
95% of children received both MCV and VCV before age 4 years.
Significantly fewer children who initially received VAR alone later received a MCV before age 4 years.
Clinical Implications
The findings highlight the need for continued monitoring of vaccine uptake among diverse populations to ensure equitable access to recommended vaccinations. The demographic trends observed may inform public health strategies to address potential gaps in immunization coverage.
Conclusion
The study underscores the importance of understanding vaccine selection patterns and their implications for public health, particularly in light of upcoming changes to vaccination recommendations.
A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.
